

PUBLICATIONS

- Atayde A, Hauc SC, **Bessette LG**, Danckers H, Saitz R. "Changing the narrative: a call to end stigmatizing terminology related to substance use disorders." Accepted for publication in *Addiction Research and Theory*.
- Patorno E, Pawar A, **Bessette LG**, Kim DH, Dave C, Glynn RJ, Munshi MN, Schneeweiss S, Wexler D, Kim SC. "Cardiovascular and Metabolic Risk - Comparative effectiveness and safety of SGLT2 inhibitors vs. GLP-1 receptor agonists in older adults". Accepted for publication in *Diabetes Care*.
- Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, Bartels DB, Kahler K, **Bessette LG**, Schneeweiss S. "STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies." *BMJ*. 2021 Jan 12. <https://doi.org/10.1136/bmj.m4856>.
- Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, **Bessette LG**, Lee H, Garry EM, Gautam. N, Schneeweiss S. "Emulating randomized clinical trials with nonrandomized real-world evidence studies: First results from the RCT DUPLICATE initiative." *Circulation*. 2020 Dec 17. doi.org/10.1161/CIRCULATIONAHA.120.051718.
- Gautam N, **Bessette L**, Pawar A, Levin R, Kim DH. "Updating International Classification of Diseases Ninth Revision to Tenth Revision of a Claims-Based Frailty Index." *J Gerontol A Biol Sci Med Sci*. 2020 Jun 12;glaa150. doi: 10.1093/gerona/glaa150.
- **Bessette LG**, Hauc SC, Danckers H, Atayde A, Saitz R. "The Associated Press Stylebook Changes and the Use of Addiction-related Stigmatizing Terms in News Media." *Substance Abuse*. 2020 Apr 29;1-4. doi: 10.1080/08897077.2020.1748167.
- Huybrechts KF, Bateman BT, Pawar A, **Bessette LG**, Mogun H, Levin R, Li H, Motsko S, Scantamburlo Fernandes MF, Upadhyaya HP, Hernandez-Diaz S. "Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study." *BMJ*. 2020 Feb 19;368:m237. doi: 10.1136/bmj.m237.
- Patorno E, Najafzadeh M, Pawar A, Franklin JM, Déruaz-Luyet A, Brodovicz KG, Santiago Ortiz A, **Bessette LG**, Kulldorff M, Schneeweiss S. "The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study program: Study design, validity, and exposure accrual for a real-world evaluation of empagliflozin in routine clinical care." *Endocrinol Diabetes Metab*. 2019 Nov 26;3(1):e00103. doi: 10.1002/edm2.103. eCollection 2020 Jan.
- Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, **Bessette LG**, Santiago Ortiz A, Kulldorff M, Schneeweiss S. "Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study." *Circulation*. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.

PRESENTATIONS

- **Co-Author**, "Personal History of Febrile Seizure Increases Risk of Measles-Mumps-Rubella Vaccine Attributable Seizure." Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE All Access 35 Years of Real-World Science; 2020 September; Online.
- **Co-Author**, "Effectiveness and safety of empagliflozin in routine care patients: interim results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study" Accepted for poster session presentation at: European Association for the Study of Diabetes EASD Virtual Meeting; 2020 September; Online.
- **Co-Author**, "Comparative Effectiveness and Safety of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists Among Real-world Older Adult." Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE All Access 35 Years of Real-World Science; 2020 September; Online.
- **Co-Author**, "Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study" Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE All Access 35 Years of Real-World Science; 2020 September; Online.
- **Co-Author**, "Reduced Healthcare Utilization in Patients Using Empagliflozin: An Interim Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study." Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management 35th ICPE; 2019 August 24-28; Philadelphia, PA.
- **Co-Author**, "Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from Theempagliflozin Comparative Effectiveness and Safety (EMPRISE) Study" Accepted for oral presentation at: International Conference on Pharmacoepidemiology & Therapeutic Risk Management 35th ICPE; 2019 August 24-28; Philadelphia, PA.
- **Co-Author**, "Empagliflozin Selected Cardiovascular And Safety Outcomes In Routine Care: First Results From the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study." Accepted for oral presentation at: American Diabetes Association 79th Scientific Sessions; 2019 June 7-11; San Francisco, CA.
- **Co-Author**, "Healthcare Costs And Medication Burden In Routine Care Initiators Of Empagliflozin: A First Analysis From the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study." Accepted for poster session presentation at: American Diabetes Association 79th Scientific Sessions; 2019 June 7-11; San Francisco, CA.
- **Co-Author**, "Real-world Effectiveness Of SGLT2 Inhibitors Vs GLP-1 Receptor Agonists In Patients With And Without Cardiovascular Disease." Accepted for oral presentation at: American Diabetes Association 79th Scientific Sessions; 2019 June 7-11; San Francisco, CA.
- **Co-Author**, "Risk-benefit Of SGLT2 Inhibitors (SGLT2i) vs GLP-1 Receptor Agonists (GLP-1 RA) In Routine Care Of Older Adults." Accepted for oral presentation at: American Diabetes Association 79th Scientific Sessions; 2019 June 7-11; San Francisco, CA.
- **Co-Author**, "Comparative healthcare costs and medication burden in real-world patients augmenting metformin monotherapy with empagliflozin from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study." Accepted for poster session presentation at: AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019; 2019 March 25-28; San Diego, CA.
- **Co-Author**, "Reduced healthcare utilization in patients using empagliflozin: an interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study." Accepted for poster session presentation at: AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019; 2019 March 25-28; San Diego, CA.
- **Co-Author**, "Healthcare costs in patients using empagliflozin: an interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study." Accepted for poster session presentation at: AMCP Managed Care & Specialty Pharmacy Annual Meeting 2019; 2019 March 25-28; San Diego, CA.

- **Co-Author**, “Comparative Effectiveness And Safety Of Empagliflozin: an interim analysis from the EMPagliflozin compaRative effectlveness and SafEty (EMPRISE) Study.” Accepted for poster session presentation at: American College of Cardiology Scientific Session (ACC.19); 2019 March 16-18; New Orleans, LA.
- **Presenter and Co-Author**, “Characterization of anti-SIV monoclonal antibody SU24 cloned into a mammalian expression vector.” Poster session presented at: Boston College 2018 Undergraduate Symposium; 2018 May 4; Chestnut Hill, MA.
- **Presenter and Co-Author**, “Characterization of putative efflux pump genes in *Acinetobacter baumannii*.” Poster session presented at: Boston College 2018 Undergraduate Symposium; 2018 May 4; Chestnut Hill, MA.
- **Presenter and Co-Author**, “Evolutionary Conservation of the *Neurospora crassa Met16* Gene Through the Complementation of a *Saccharomyces cerevisiae met16* Mutant.” Poster session presented at: Boston College 2017 Undergraduate Research Day; 2017 May 5; Chestnut Hill, MA.